Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing s Q4 Revenues Jump on Sales of PSQ Sequencing System

NEW YORK, Feb 22 - Pyrosequencing, a manufacturer of DNA sequencing equipment based in Uppsala, Sweden, reported Thursday fourth quarter revenes ot $2.7 million, compared with $116,525 million in the year ago period, due to sales of the company's flagship product, the PSQ 96 DNA sequencing system.

For the year, net sales totalled $4.9 million, compared with $137,712 a year ago. Pyrosequencing launched the PSQ 96 DNA system last February and has since sold 53 of these systems and received orders for seven more.

"We believe that in the first year of sales we have established the PSQ 96 system as the dominant offering in the moderate throughput segment of the DNA sequencing market," Erik Wallden, CEO of Pyrosequencing, said in a statement.

Operating losses for the fourth quarter of 2000 widened to $3.1 million from $2.0 million in the fourth quarter of 1999. Total net losses stayed constant at $2.0 million compared to the year ago quarter. On a per share basis, net losses narrowed to six cents per share from 17 cents per share. The company reported 2000 losses of 32 cents per share, compared to net losses of 59 cents per share in 1999.

Purchasers of the PSQ 96 include the NIH, AstraZeneca, and GlaxoSmithKline. In addition to the PSQ 96, Pyrosequencing also offers a high throughput SNP detection technology known as the Preferred Technology Program. The Wallenberg Consortium North, a group of Swedish academic and public research institutions, is currently the lone subscriber.

As of December 31, 2000, Pyrosequencing said it had $41.3 million in cash and cash equivalents in the bank.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.